- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04070313
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer.
- Primary Endpoint: Relapse-free survival (RFS)
- Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Linkou, Taiwan
- Chang Gung Memorial Hospital_Linkou
-
Tainan, Taiwan
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital, Taiwan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with resected adenocarcinoma pancreatic cancer that was histologically verified.
- Patients with macroscopic total resection of the primary tumor, and confirmed local residual tumor classified as R0/R1.
- Absence of distant metastases and malignant ascites
- Adequate oral intake
- Age of 20 years or above
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or1
Adequate hematopoietic which is defined as below,
- White blood cell count: 3,000/mm3, ≤ 12,000/mm3
- Platelet count: 100,000/mm3
- Hemoglobin: 8.0 g/dL
- ANC: 1500/mm3
- CA19-9 ≤ 100 U/mL
- Absence used of chemotherapy or radiotherapy
- Within 10 weeks following resection of pancreatic cancer
- Written informed consent given
Exclusion Criteria:
- Patient previously received adjuvant therapy for pancreatic cancer
- Patient previously received S-1 treatment and concurrent using other fluoropyrimidine-group anti-cancer drugs, combination therapies with them (such as folinate plus Tegafur-Uracil combination therapy)
- Recurrence prior to registration
- Moderate or more severe pleural effusion or ascites upon abdominal CT
Inadequate hepatic function which is defined as below:
- Total bilirubin greater than 1.5 times the ULN
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)greater than 2.5 times the ULN
Inadequate renal function which is defined as below:
Creatinine clearance rate (CCr) < 60 mL/min
- Heart failure of Class III (Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.) or Class IV (Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.) according to the New York Heart Association functional classification
- Other serious complications such as active peptic ulcer, paresis of intestine or any others
- Pulmonary fibrosis or interstitial pneumonia clearly observed
- Uncontrolled watery diarrhea Whether a patient has diarrhea 4 or more times a day while receiving adequate supportive therapy will be used as the indicator to determine whether watery diarrhea is inadequately controlled.
- Blood transfusion within 2 weeks prior to registration
- Myocardial infarction within 6 months following documentation of pancreatic cancer
An active infectious disease (pyrexia of 38°C or higher, etc.), including active Hepatitis B or C.
- Active HBV: HBeAg positive or HBeAg negative but HBV DNA > 2000 IU/mL.
- Active HCV: Anti-HCV Ab positive
Poorly controlled diabetes mellitus:
Fasting blood sugar ≥ 200 mg/dL or HbA1c ≥ 10.0 %
- Participation in the study by the patient is judged difficult due to a complicating psychiatric disorder or psychological symptoms
- Patient is using drainage.
- Serious drug allergy or hypersensitivity to the ingredients of S-1
- Other malignancy with the exception of non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to registration
- Pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Fertile women of childbearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period and for three months following cessation of treatment.
- Man who is willing to conceive a child during the treatment period.
- On flucytosine, phenytoin or warfarin potassium treatment.
- Participation in another clinical trial with any investigational drug within 30 days prior to registration.
- Patients who were judged to be ineligible as the subjects of this study by the investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: S-1
single-arm
|
Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-free survival (RFS)
Time Frame: 2 years
|
The time from registration to the time of initial detection of relapse or death from any causewhichever came first, assessed up to 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year survival rate
Time Frame: 2 years
|
The number of patient who occur relapse or death from any cause, whichever comes first before end of 2 years
|
2 years
|
2-year relapse-free survival (RFS) rate
Time Frame: 2 years
|
the percentage of people in a study who are alive 2 years after their diagnosis or the start of treatment
|
2 years
|
safety profile
Time Frame: 2 years
|
The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v5.0 grade
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TTYTG1709
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on S-1
-
Tomoshi TsuchiyaCompleted
-
Fudan UniversityThe First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... and other collaboratorsWithdrawn
-
Sun Yat-sen UniversityUnknown
-
Peking University Cancer Hospital & InstituteRecruiting
-
Taiho Oncology, Inc.Quintiles, Inc.; United BioSource, LLCCompletedAdvanced Non-Small Cell Lung Cancer
-
Hamamatsu UniversityUnknownGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Colon CancerJapan
-
Zhejiang Cancer HospitalCompleted
-
Taiho Oncology, Inc.Quintiles, Inc.; United BioSource, LLCCompletedLocally Advanced or Metastatic Pancreatic Cancer
-
Fudan UniversityCompletedNasopharyngeal CarcinomaChina
-
Seoul National University Bundang HospitalUnknown